Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 8/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21206316 | 0.92 | SMYD3 (0.40) | MAPK1MEN1TSHRKMT2ASMYD3 | |
| SCHEMBL24125043 | 0.87 | SMYD3 (0.37) | MAPK1MEN1TSHRKMT2ASMYD3 | |
| SCHEMBL25447017 | 0.87 | GLS (0.38) | MAPK1MEN1TSHRKMT2ASMYD3 | |
| SCHEMBL25447013 | 0.85 | GLA (0.37) | MAPK1MEN1TSHRKMT2ASMYD3 | |
| SCHEMBL26409868 | 0.75 | CYP2C19 (0.42) | CYP2C19ALDH1A1LMNAGLS | |
| SCHEMBL13154688 | 0.71 | TSHR (0.41) | MAPK1MEN1TSHRKMT2ACYP2C19 | |
| SCHEMBL24334700 | 0.71 | GLS (0.48) | MAPK1CYP2C19GLS | |
| SCHEMBL25446979 | 0.67 | KMT2A (0.38) | MAPK1MEN1TSHRKMT2ACYP2C19 | |
| SCHEMBL10074426 | 0.66 | POLB (0.46) | MEN1KMT2ACYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL4782298 | 0.66 | SMYD3 (0.40) | MAPK1SMYD3CYP2C19GLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210323990-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323990-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | MAPK1 3831/4885MEN1 2861/4885TSHR 2178/4885 |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | MAPK1 3949/4885MEN1 2369/4885TSHR 1887/4885 |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | MAPK1 3831/4885MEN1 2861/4885TSHR 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.